Business Daily from THE HINDU group of publications Tuesday, Feb 26, 2008 ePaper | Mobile/PDA Version |
|
|
|
|
|
|
|
Corporate
-
New Business Jubilant bags $92-m worth contract research deals Our Bureau New Delhi, Feb. 25 Jubilant Organosys Ltd has got new contracts worth $92 million under its custom research and manufacturing services business for the calendar year 2008. Given Jubilant’s geographical focus on the regulated markets, a large percentage of these contracts are realisable from the US, Europe and Japan. Outside the geographical region of the regulated markets, China is a major market for Jubilant. “Jubilant’s order book for the calendar year stands further augmented with the addition of these contracts –the increase in size, over a similar announcement made last year, is over 50 per cent. The new contracts have been signed with major international pharma and other life sciences companies,” said a company statement. Product pipelineThe company said it had a healthy pipeline of products which are in Phase III (stage of development at the customers end); and to support this it has made timely investments to expand key capacities. These contracts represent a huge opportunity for volume growth going forward for the exclusive synthesis and contract manufacturing segments under CRAMS. Mr Shyam S. Bhartia, Chairman and Managing Director, Jubilant Organosys, said: “The signing of the recent agreements is expected to translate into considerable improved performance in the key pharma and life sciences products segment during calendar 2008.” More Stories on : New Business | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
![]() |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2008, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|